Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12354 clinical trials
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

The purpose of this phase I/Ib study is to determine the safety profile of NIZ985 (new formulation), and if it can be safely combined with Spartalizumab and to determine the appropriate dose and schedule for further study. Moreover, the study will characterize the pharmacokinetic profiles of NIZ985 as a single …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

absolute neutrophil count
bone marrow biopsy
igm level
ibrutinib
venetoclax
  • 0 views
  • 19 Feb, 2024
  • 2 locations
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2

This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with neurofibromatosis type 2 (NF2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow …

conventional mri
nf2 gene
brigatinib
investigational drug
acoustic neuroma
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.

hodgkin's disease
lenalidomide
non-hodgkin lymphoma
b-cell lymphoma
lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell Lymphoma

The purpose of this study is to determine the Predictive value of a SNP signature and liquid biopsy in patients with natural killer T-cell lymphoma.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma

The purpose of this study is to determine the predictive value of a mRNA signature and liquid biopsy in patients with Diffuse Large B cell lymphoma.

b-cell lymphoma
lymphoma
diffuse large b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant. Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a …

  • 0 views
  • 19 Feb, 2024
  • 31 locations
Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies

Development of CAR-T cell against CD19 B lymphoma and Acute Lymphoblastic Leukemia leaded to 2 authorized medication: Yescarta and Kymriah. Despite impressive outcomes in 3 phase II studies, never met in relapsed or refractory diseases, half of the patients don't respond to this treatment.This can be explained by a low …

  • 0 views
  • 19 Feb, 2024
  • 1 location